logo
Oakland clears homeless encampment, moves 70 to shelter — but advocates say city's outreach efforts fell short

Oakland clears homeless encampment, moves 70 to shelter — but advocates say city's outreach efforts fell short

Yahoo3 days ago

The City of Oakland has cleared a large homeless encampment on East 12th Street, relocating about 70 people to the Mandela House — a former hotel turned shelter, now funded through a state grant.
The move marks one of the city's most visible steps toward addressing homelessness, a crisis that has more than doubled in Oakland over the past decade.
Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 5 of the easiest ways you can catch up (and fast)
Nervous about the stock market in 2025? Find out how you can access this $1B private real estate fund (with as little as $10)
Driven by rising rents, stagnant wages and a chronic shortage of affordable housing, more than 4,000 people in the city are currently unhoused.
Oakland officials say the clearance is part of a broader push to connect unhoused residents with long-term housing support. It follows Governor Gavin Newsom's rollout of a model ordinance aimed at helping cities respond to what he calls the 'dangerous' and 'unhealthy' conditions of encampments.
'There's nothing compassionate about letting people die on the streets,' Newsom said in a press release. 'Local leaders asked for resources — we delivered the largest state investment in history.'
As Oakland aligns with statewide efforts to address homelessness, the impact of encampment closures — and whether they help — remains at the center of the conversation.
California's homelessness crisis has reached a breaking point. According to data from the U.S. Department of Housing and Urban Development, more than 187,000 people were homeless in the state last year — nearly 24% of the entire nation's unhoused population. The pressure is mounting on state and local leaders to act fast.
In response, Newsom announced $3.3 billion in new funding to help cities expand access to housing and treatment for the state's most vulnerable.
Cities like Oakland and San Francisco are rolling out targeted interventions. San Francisco's newly elected mayor, Daniel Lurie, has pledged to tackle homelessness head-on. Oakland is already home to the Community Cabins program — a shelter initiative offering small, two-person cabins built on public land.
These temporary shelters focus on stabilization and connecting residents to long-term support. The program has seen high participation rates, largely because cabins are built near existing encampments, allowing people to stay close to familiar spaces.
'Oakland's Cabin Community model is one of the most promising and cost-effective homeless shelter innovations I've seen,' said Trent Rhorer, executive director of the San Francisco Human Services Agency.
Read more: Want an extra $1,300,000 when you retire? Dave Ramsey says — and that 'anyone' can do it
City officials say closing the East 12th Street encampment is a step forward, but community reactions suggest a more complicated reality.
Some residents and business owners say they're relieved to see the area cleared, calling it a long-standing source of frustration.
"I was driving by, and I was shocked to see the whole encampment was clean," said Veleda, an Oakland resident, in an interview with Fox KTVU. "It was an eyesore, and it was very hard for them to tackle it."
But homeless advocates say that while shelters like Mandela House or Community Cabins represent a step in the right direction, the process of clearing encampments often unfolds with little warning and limited resources.
"People lost medication, people lost their IDs, people lost their phones, people lost their clothing, their food," Needa Bee, director of the homeless advocacy group, The Village, told Fox KTVU. According to Bee, she was able to reconnect with 54 individuals from the East 12th encampment — none of whom were offered housing options before the site was cleared.
The city maintains that shelter space was made available at Mandela House. But advocates argue the outreach efforts fell short, and question how effective these emergency responses really are in the long term.
With growing pressure to 'clean up' encampments, cities risk swapping long-term solutions for short-term optics — and sidelining the very people these efforts claim to support.
Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you?
Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead
Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now
This is how American car dealers use the '4-square method' to make big profits off you — and how you can ensure you pay a fair price for all your vehicle costs
Like what you read? Join 200,000+ readers and get the best of Moneywise straight to your inbox every week.
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Israel-Backed Gaza Aid Group Suspends Operations for Second Day
Israel-Backed Gaza Aid Group Suspends Operations for Second Day

Bloomberg

time38 minutes ago

  • Bloomberg

Israel-Backed Gaza Aid Group Suspends Operations for Second Day

An Israel- and US-backed mechanism to distribute food in Gaza suspended operations for a second day following a series of deadly incidents near its sites that drew international criticism. The Gaza Humanitarian Foundation, a Swiss-based nonprofit, launched in Gaza last week following a months-long Israeli blockade of the territory, and says it has handed out enough food staples for millions of meals. But the roll-out has been dogged by overcrowding and at least one incident in which Israeli forces, citing a security threat, fired toward Palestinians headed to a GHF aid center.

Catching Resistance Early: Can New Breast Cancer Drug Help?
Catching Resistance Early: Can New Breast Cancer Drug Help?

Medscape

time41 minutes ago

  • Medscape

Catching Resistance Early: Can New Breast Cancer Drug Help?

CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? Interim findings from the SERENA-6 trial suggest that may be the case. Patients who switched from a first-line aromatase inhibitor to camizestrant, an investigational next-generation oral selective estrogen-receptor degrader, at the first signs of an emerging ESR1 mutation demonstrated significantly improved progression-free survival compared with those who continued their initial regimen. Notably, circulating tumor DNA (ctDNA) testing allowed investigators to identify ESR1 mutations, which emerge at the time of disease progression in about 40% of patients on a first-line aromatase inhibitor and lead to treatment resistance. Camizestrant, which has shown activity in patients who develop ESR1 mutations, helped improve first-line outcomes and has 'potential to become a new treatment strategy,' according to co-principal investigator Nicholas Turner, MD, PhD, professor and honorary consultant in medical oncology at the Institute of Cancer Research and Royal Marsden Hospital, London, England, who presented the findings at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. Results were simultaneously published in The New England Journal of Medicine . This trial also demonstrated 'the clinical utility of ctDNA monitoring to detect and treat emerging resistance in breast cancer,' said Turner. While praising the findings, others were not convinced that the SERENA-6 results warrant a change in practice yet. 'Based on first-line progression-free survival alone, this could represent a new regulatory approval path,' said invited discussant Angela DeMichele, MD, of the University of Pennsylvania, Philadelphia. But, DeMichele cautioned, 'I cannot recommend the SERENA-6 strategy at this time.' One key reason, DeMichele noted, is that it's too early to tell whether this strategy improves overall survival. If camizestrant is approved based on progression-free survival and quality of life, DeMichele wondered, is it worth going through the ctDNA testing process if the drug doesn't help patients live longer? Paolo Tarantino, MD, a breast oncologist at Dana-Farber Cancer Institute and Harvard Medical School in Boston, echoed this sentiment in a tweet on X: 'Outstanding results, though not ready for clinical practice (yet),' adding that it will also be 'important to take into account financial, psychological, and systemic costs of the strategy.' Using ctDNA to Track Resistance In the study, 3256 patients who had received at least 6 months of treatment with aromatase inhibitors and CDK4/6 therapy (palbociclib, ribociclib, or abemaciclib) received ctDNA testing with Guardant360 CDx every 2-3 months at the time of routine staging exams. Overall, 315 patients who had an ESR1 mutation detected and had no radiologic evidence of disease progression were randomly assigned to either switch from the aromatase inhibitor to 75 mg of camizestrant daily (n = 157) or continue their aromatase inhibitor/CDK4/6 regimen (n = 158). (An additional 233 patients who had an ESR1 mutation detected were not included for a variety of reasons, including disease progression and consent withdrawal.) At the planned interim analysis, the median progression-free survival was 16.0 months in the camizestrant group and 9.2 months in the aromatase inhibitor group (adjusted hazard ratio [aHR], 0.44; P < .00001). At 24 months, only 5.4% of patients who had continued their initial first-line treatment had not progressed compared with 30% of patients on camizestrant. The progression-free survival findings were consistent across clinically relevant patient subgroups. Patients who switched to camizestrant also showed improved time to deterioration in global health status and quality of life — a median of 23.0 months vs 6.4 months in the aromatase group (aHR, 0.53). At the time of the interim analysis, overall survival data were immature, with 20 deaths in the camizestrant group and 19 in the aromatase inhibitor group (HR, 0.91; 95% CI, 0.48-1.73). As for time to second progression, there were 38 events in the camizestrant group and 47 events in the aromatase group, but the findings were also immature. As for adverse events, 60% of patients in the camizestrant group had a grade 3 or higher event, 10% of which were deemed serious compared with 46% in the aromatase group, 12% of which were serious. Neutropenia (45% vs 34%, respectively) and anemia (5% in both groups) were the most common grade 3 or higher adverse events. Only 1% of patients on camizestrant discontinued treatment due to adverse events. Overall, Turner concluded that 'for people with HR-positive advanced breast cancer, the results of SERENA-6 show that camizestrant plus CDK4/6 inhibitor could be a new treatment option to use at the point of ESR1 mutation detection during treatment with first-line aromatase inhibitor plus CDK4/6 inhibitor — but before the cancer grows.' Despite the promising findings, DeMichele highlighted several key unanswered questions and challenges. Notably, will this strategy lead to longer overall survival and demonstrate clinical utility? Overall survival and time to second progression are currently not known, DeMichele said. The trial did not address whether first-line treatment gains would be lost if camizestrant was given in the second-line setting after anatomic progression. DeMichele also noted the high cost and potential anxiety associated with serial ctDNA testing. Overall, 'the full complement of financial, psychological, and systemic costs is needed to fully assess utility and feasibility for implementation,' she added. SERENA-6 was supported by AstraZeneca. Turner disclosed consulting or advisory roles with AstraZeneca, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inivata Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, and Roche. DeMichele disclosed a consulting or advisory role with Pfizer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store